- FUJIFILM Diosynth Biotechnologies is making a multibillion-dollar investment to expand global cell culture capacity, including 30+ 20,000 L bioreactors in Denmark and the USA, with further expansions in the UK and Texas
- These expansions aim to meet clinical and commercial demand, with capacity volumes of up to 5,000 L
- The KojoX strategy drives global alignment, improving agility to handle demand fluctuations while enhancing cost efficiency
- A single Quality Management System (QMS) and harmonized documentation across similar, validated equipment at nearly identical sites ensure streamlined operations
- This strategy enhances delivery speed and ensures patients access medicines quickly and efficiently
John Stewart
Vice President, KojoX™ Strategy
FUJIFILM Diosynth Biotechnologies
John Stewart, Vice President KojoX Strategy, serves as part of the Global Strategic Business Services group at FUJIFILM Diosynth Biotechnologies. His responsibilities include the execution of the Company’s novel KojoXTM Strategy. John is an executive with 30 years tenure in the pharmaceuticals industry with a background in international multi-site leadership of both small molecule and biologics manufacture and supply networks and with responsibility for internal and external manufacturing of clinical and commercial stage biologics.
—
FUJIFILM Diosynth Biotechnologies
FUJIFILM Diosynth Biotechnologies is an industry-leading cGMP Contract Development and Manufacturing Organization (CDMO) supporting the biopharmaceutical industry in the development and production of biologics, vaccines and advanced therapies. Our focus is to combine technical leadership in process development and cGMP manufacturing supported by a strong team of over 4,000 employees and a reputation for excellent customer service. We are a trusted partner of many clients, from early stage biotechs to large pharma.
